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We report here the discovery, synthesis and screening results of the series of 3-bulky 
substituted pyrrolidine-2,5-dione derivatives as a novel class of potential inhibitors on InhA, a key 
enzyme involved in the fatty acid biosynthesis pathway (type II) of M. tuberculosis as well as 
inhibitors of Mycobacterium tuberculosis H37Rv.  
Introduction 
Tuberculosis (TB) is the leading cause with 
malaria and AIDS of worldwide mortality [1]. 
The effectiveness of current anti-tuberculosis 
drugs to combat this infection is severely 
compromised by the emergence of multi- and 
extensively drug-resistant tuberculosis (MDR-
TB [2,3] and XDR-TB [4]). Therefore, more 
new drugs are required to raise the probability 
to shortly stop all forms of drug-resistant TB. It 
is in this context that many studies are based on 
targeting the cell wall of mycobacteria and more 
particularly of the components essential to their 
survival. The fatty acid synthase system of M. 
tuberculosis contains unique signature fatty 
acid, the mycolic acid, which is central 
constituent of the mycobacterial cell wall. 
Mycolic acid biosynthesis is carried out by 
several successive enzymatic cycles 
corresponding to two related but distinct Fatty 
Acid Synthase (FAS) systems, FAS I and II [5]. 
The InhA protein (ENR, EC number: 1.3.1.9) is 
a part of FAS II and shows a NADH-dependent 
enoyl-ACP reductase activity. InhA is a good 
target as the FAS II system is present in bacteria 
but is absent in humans. It is already the target 
of the first line drug isoniazide. 
In the course of our study of Michael reaction 
with maleimides as dienophiles [6-8], we were 
interested in involving succinimide fragment as 
promising core of new potential inhibitors of 
InhA protein. Michael conjugate addition is well 
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known as effective method in the synthesis of 
pharmaceutical intermediates, peptide 
analogues, antibiotics and other drugs [9,10]. In 
addition, molecules containing succinimide 
fragment are frequently employed in drug 
design. For example, 2,5-pyrrolidinedione are 
core structural units found in natural products 
and also in some approved drugs and clinical 
drug candidates [9,11,12]. Compounds such 
Moiramide B and Andrimide (Fig. 1) have been 
described as new highly specific antibiotics [13] 
exhibiting potent antibacterial activity against 
methicillin-resistant Staphylococcus aureus and 
a range of other antibiotic-resistant human 
pathogens. It was defined that Moiramide B and 
Andrimide target FAS system that is also the 
primary target for antitubercular drugs [14]. 
Moreover, Hirsutellone A (Fig. 1) a natural 
product bearing succinimide ring is reported to 
display significant growth inhibitory activity 
against Mycobacterium tuberculosis H37Ra 
strain [15].  
 
 
 
Figure 1. Structures of natural antibiotics 
(Moiramide B and Andrimide) and 
antimycobacterial alkaloid Hirsutellone A. 
Here we report synthesis and biological 
evaluation of a series of bulky 3-heteryl 
substituted pyrrolidine-2,5-diones. 
Results and discussion 
Compounds described in Table 1 were 
synthesized by Lewis acid catalyzed Michael 
reaction on the maleimide core via NH or C-H 
heterocyclic modifications. A methodological 
approach has already been reported by us [16, 
17] then evaluated and applied in the cases 
presented here. 
Compounds 3a-b as well as compounds 4a-b 
were obtained via C–N conjugate addition of 1-
(9H-fluoren-9-yl)piperazine and 1,2,3,4-
tetrahydroisoquinoline respectively to N-
substituted maleimides (Scheme 1). 
Scheme 1. Synthesis of C–N Michael adducts. 
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The best results were obtained when using a 
catalytic amount of lithium perchlorate (LiClO4) 
in dry dioxane at room temperature (method A). 
Alternative way to the synthesis of adducts 
described on scheme 1 was applied. To check 
efficacy of our catalytic approach we provide 
the reaction in isopropyl alcohol with 0.5 
equivalents of Hünig’s base and the yields 
obtained in this case were lower than previously 
(method B). Compounds 3a and 3b were 
synthesized as analogues of known selective 
nanomolar inhibitor of InhA protein GEQ 
(Genz-10850) (Fig 2) [15].  
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Figure 2. Structure of nanomolar inhibitor of InhA. 
IC50 (InhA) = 0.16 M; MIC > 30 M [18]. 
The synthesized compounds 3a and 3b contain a 
bulky and rigid fluorene along with a piperazine 
moiety as it is the case of GEQ. The fluorenyl 
ring plays as an anchor in the binding site of 
InhA and is responsible for extensive 
hydrophobic interactions [18]. 
Then, Michael addition was carried out between 
maleimide derivatives and two C-H active 
heterocycles i.e. 2-phenylindolizine and 7,9-
dinitropyrido[2,1-a]isoindole that are shown on 
the scheme 2. The reaction progress was 
followed by TLC till consumption of the 
starting material. It is noteworthy that in this 
case when using LiClO4 as catalyst, only traces 
of the desired products were obtained. 
Apparently, LiClO4 is not as effective as 
catalyst for C–C addition. Different other Lewis 
acids have then been tested (AlCl3, ZnCl2 or 
TiCl4). The best results were obtained when 
using a catalytic amount of AlCl3 under reflux 
conditions in dry dioxane, affording compounds 
6a, 6b and 8 in 84%, 71% and 62% yields, 
respectively after recrystallization (Table 1). 
 Scheme 2. Synthesis of C–C Michael adducts. 
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Table 1. Structure of synthesized compounds and 
yields of the products 
Cpds Structure Yield (%) 
3a 
N
N
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O  
88 (Method A) 
70 (Method B) 
3b 
N
N
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58 (Method B) 
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55 (Method B) 
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All the synthesized compounds were evaluated 
by determining the minimal inhibitory 
N
N
O
N
H
GEQ (Genz-10855)
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concentration (MIC) on M. tuberculosis H37Rv 
strain. They were also evaluated in vitro as 
potential InhA inhibitors at 50 µM by applying 
a commonly used method [18]. Recombinant M. 
tuberculosis InhA was expressed in E. coli and 
subsequently purified according to a previous 
reported procedure [19, 20]. 
The results are shown in Table 2. Triclosan and 
GEQ were used for comparison. Compounds 
3a-b present the best activities on InhA protein 
among the tested derivatives, nevertheless the 
values are still too modest compared to that of 
GEQ. Docking studies for compound 3a were 
done and some possible differences in binding 
are shown compared to GEQ (PDB ID 1P44). 
From the alignment of the predictive binding 
modes, we could summarize that 3a could be 
inserted in the active site but through a different 
geometry. Indeed, the fluorenyl ring could not 
exactly match the large hydrophobic pocket of 
InhA protein (Fig 3). It is also worth mentioned 
that electrostatic interactions and hydrogen 
bonding between 3a and cofactor NAD+ are 
missing. 
Compound 8 shows an inhibitory activity 
equivalent to compounds 3a and 3b. It is 
noteworthy that compound 8 as compounds 3a 
and 3b bear rigid tricyclic 7,9-dinitro 
pyrido[2,1-a]isoindolyl and fluorene rings, 
while in the contrary compounds 4a, 4b and 6a, 
6b have more flexible and non planar moieties.   
 
Figure 3. Alignment of binding mode of GEQ (pdb 
ID 1P44, carbons in grey sticks) and predicted 
binding pose of 3a (carbons in green sticks) into the 
binding site of InhA (surface representation colored 
by electrostatic interaction). Cofactor NAD
+
 is in 
stick representation with carbons colored in violet. 
 
Table 2. Enzyme inhibition values. Results are 
expressed as a percentage of InhA inhibition. 
Minimal inhibitory concentration (MIC) values on 
M. tuberculosis H37Rv strain. 
Compound % Inhibition 
(at 50 M) 
MIC 
(µg/ml) / (µM) 
Triclosan >99 10 / 34.5 
GEQ >99 >60 / >150 
3a 52 40 / 94.4 
3b 56 40 / 91.4 
4a 20 2.5 / 8.2 
4b 16 10 / 31.2 
6a Nd* 40 / 109.2 
6b Nd* 20 / 52.6 
8 45 >16 / >37.2 
*not determined values 
 
Finally, the MIC values of compounds 3a, 3b, 
6a and 6b are in the same range but better than 
that of GEQ compound. The promising results 
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of MIC values were obtained for compounds 4a 
and 4b that are even better than Triclosan. Thus 
structures of those inhibitors are point of interest 
for further development of effective 
antituberculosis agents. 
Conclusion 
A series of 3-bulky substituted 
pyrrolidine-2,5-dione derivatives have been 
synthesized using optimized catalytic conditions 
for Michael addition. Synthesized compounds 
were assayed for in vitro inhibition of InhA and 
M. tuberculosis growth. 
Experimental part 
Materials and Methods 
 Kinetic studies were perfomed on a Cary 
Bio 100. All chemicals were obtained from 
Aldrich or Acros Organics and used without 
further purification. Nuclear magnetic 
resonance spectra were recorded on a Bruker 
AC 300 spectrometer (1H and 13C NMR), 
solvent residue signals were used for 
calibration of spectral data. Mass 
spectrometry (MS) data were obtained on a 
ThermoQuest TSQ 7000 spectrometer, high-
resolution mass spectra (HRMS) were 
recorded on a ThermoFinnigan MAT 95 XL 
spectrometer using electrospray ionization 
(ESI) methods. Melting points were measured 
on a Mettler Toledo MP50 melting point 
system and are uncorrected. 1-(9H-fluoren-9-
yl)piperazine and GEQ compound (genz-
10850) was synthesized according to the 
literature procedure [18]. 
InhA expression and purification. The 
production and purification were performed as 
described in reference [20].  
Inhibition Kinetics  
All activity assays were performed in 
triplicate in accordance to the reference 
procedure [20]. 
Growth conditions  
M. tuberculosis H37Rv strain was grown either  
MIC determinations. The procedure was 
performed as described in the reference [19].  
1-(9H-fluoren-9-yl)piperazine (1), 2-phenyl-
indilisine (5) and 7,9-dinitropyrido[2,1-
a]isoindole (7) were synthesized according to 
the references [18, 21, 22], respectively. 
General procedure for C–N Michael addition 
(Method A) To a solution of N-substituted 
maleimide (0.22 mmol) in dry dioxane, LiClO4 
(6 mg) was added. Then a solution of 1-(9H-
fluoren-9-yl)piperazine or 3,4-
dihydroisoquinoline (0.19 mmol) in dry dioxane 
was added. The mixture was stirred overnight at 
room temperature. The reaction progress was 
controlled by TLC. After completion, the 
solvent was evaporated and the crude product 
was purified by flash chromatography. 
Method B To a solution of amine (0.28 mmol) 
in iPrOH, N-phenyl maleimide (0.34 mmol) was 
added. After 10 min stirring, N,N-
diisopropylethylamine (Hünig’s base) was 
added (0.15 mmol). The reaction mixture was 
stirred overnight at room temperature. Then the 
solvent was evaporated and the corresponding 
crude product was purified by flash 
chromatography. 
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3-[4-(9H-Fluoren-9-yl)-1-piperazinyl]-1-
phenyl-2,5-pyrrolidinedione (3a) 
The crude product was purified by flash 
chromatography (CH2Cl2/EtOAc–8:2) to give 
lightly yellow crystals. Yield: (Method A) 88%, 
(Method B) 70%; mp: 191 0C. 1H NMR (300 
MHz, CDCl3): δ = 2.61–3.04 (m, 10H), 3.92 
(dd, J = 4.8 Hz, J = 9.0 Hz, 1H), 4.85 (s, 1H), 
7.24–7.49 (m, 9H), 7.63–7.10 (m, 4H). 13C 
NMR (75 MHz, CDCl3): δ = 32.1, 43.2, 48.9, 
49.9, 62.6, 69.9, 119.9, 126.2, 126.6, 127.2, 
128.4, 128.9, 129.3, 131.6, 141.2, 175.1, 181.8. 
HRMS: calculated for C28H29N3O2 439.5488; 
found 439.5472. 
1-Benzyl-3-[4-(9H-fluoren-9-yl)-1-piperazinyl]-
2,5-pyrrolidinedione (3b)  
Yield: (Method A) 83%, (Method B) 58%; mp: 
168 0C. 1H NMR (300 MHz, DMSO-d6): δ = 
2.52–2.99 (m, 10H), 3.81 (dd, J = 4.5 Hz, J = 
9.0 Hz, 1H), 4.53 (s, 2H) 4.77 (br. s, 1H), 7.25–
7.67 (m, 13H). 13C NMR (75 MHz, CDCl3): δ = 
32.0, 48.9, 49.5, 50.5, 62.2, 69.8, 120.0, 126.1, 
126.6, 127.1, 128.4, 128.9, 129.3, 131.5, 140.9, 
174.5, 179.8. 
3-(3,4-Dihydroisoquinolin-2(1H)-yl)-1-
phenylpyrrolidine-2,5-dione (4a) 
The product was recrystallized from isopropyl 
alcohol to give a white powder. Yield: 87%; 
mp: 149 0C. 1H NMR (300 MHz, DMSO-d6): δ 
= 2.79–3.10 (m, 6H), 3.72 (d, J = 14.7 Hz, 1H), 
4.09 (d, J = 14.7 Hz, 1H), 4.27 (dd, J = 5.7 Hz, 
J = 8.7 Hz), 7.06–7.12 (m, 4H), 7.29–7.32 (m, 
2H), 7.40–7.53 (m, 3H). 13C NMR (75 MHz, 
DMSO-d6): δ = 29.0, 31.4, 46.5, 50.9, 62.2, 
125.5, 126.0, 126.4, 127.2, 128.4, 128.6, 128.9, 
132.3, 133.9, 134.5, 174.6, 175.7. MS [M+H+] 
calculated for C19H19N2O2 307.37; found 307.1 
1-Benzyl-3-(3,4-dihydroisoquinolin-2(1H)-
yl)pyrrolidine-2,5-dione (4b) 
The product was recrystallized from isopropyl 
alcohol to give lightly yellow crystals. Yield: 
79%; mp: 106.5 0C. 1H NMR (300 MHz, 
DMSO-d6): δ = 2.64–2.99 (m, 6H), 3.57 (d, J = 
14.7 Hz, 1H), 3.98 (d, J = 14.7 Hz, 1H), 4.18 
(dd, J = 5.4Hz, J = 8.4 Hz, 1H), 4.59 (s, 2H), 
6.97–7.12 (m, 4H), 7.25–7.37 (m, 5H). 13C 
NMR (75 MHz, DMSO-d6): δ = 29.0, 31.1, 
41.2, 46.4, 50.8, 61.9, 125.5, 126.0, 127.4, 
128.4, 128.5, 133.8, 134.3, 136.2, 175.3, 176.5. 
MS [M+H+] calculated for C20H20N2O2 321.39; 
found 321.1  
General procedure for C–C Michael addition 
7,9-Dinitropyrido[2,1-a]isoindole (100 mg, 0.39 
mmol) or of 2-phenylindolizine (100 mg, 0.52 
mmol) was dispersed in dry dioxane. Then N-
substituted maleimide (0.4 or 0.53 mmol 
respectively to the reagents) was added. The 
mixture was stirred for 15 minutes. Thereafter 
catalytic amount of aluminium chloride was 
added. The reaction mixture was refluxed over 6 
h with 7,9-dinitropyrido[2,1-a]isoindole and 4 h 
with 2-phenylindolizine. The reaction progress 
was monitored by TLC. After completion, the 
solvent was evaporated and the crude product 
was purified by crystallization. 
1-Phenyl-3-(2-phenyl-3-indolizinyl)-2,5-
pyrrolidinedione (6a) 
The crude product was recrystallized from 
EtOH. Yield: 84%; mp: 210 0C. 1H NMR (300 
MHz, DMSO-d6): δ = 3.06 (dd, J = 6.9 Hz, J = 
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17.7 Hz, 1H), 3.36 (m, 1H), 5.13 (t, J = 8.4 Hz, 
1H), 6.60–7.54 (m, 14H), 7.97 (d, J = 6.6 Hz, 
1H). 13C NMR (75 MHz, DMSO-d6): δ = 33.6, 
37.4, 99.6, 111.3, 114.5, 117.5, 119.1, 122.8, 
126.9, 127.1, 128.4, 128.7, 128.9, 129.0, 129.8, 
132.3, 132.5, 135.7, 174.5, 175.8. 
1-Benzyl-3-(2-phenyl-3-indolizinyl)-2,5-
pyrrolidinedione (6b) 
The crude product was recrystallized from 
EtOH. Yield: 71%; mp: 192 0C. 1H NMR (300 
MHz, DMSO-d6): δ = 3.14 (dd, J = 6.3 Hz, J = 
16.8 Hz, 1H), 3.35 (m, 1H), 4.51 (s, 2H) 5.07 (t, 
J = 9.0 Hz, 1H), 6.67–7.53 (m, 14H), 7.95 (d, J 
= 6.9 Hz, 1H). 13C NMR (75 MHz, DMSO-d6): 
δ = 33.6, 37.5, 46.6, 99.8, 111.5, 114.3, 117.1, 
118.9, 122.8, 124.9, 126.4, 127.1, 128.4, 128.7, 
128.9, 129.0, 129.8, 132.3, 132.5, 135.7, 174.1, 
175.6. 
3-(7,9-Dinitropyrido[2,1-a]isoindol-6-yl)-1-
phenyl-2,5-pyrrolidinedione (8) 
The crude product was recrystallized from 
DMSO to afford a red powder. Yield: 62%; mp: 
290 0C. 1H NMR (300 MHz, DMSO-d6): δ = 
3.27 (dd, J = 7.8 Hz, J = 18.3 Hz, 1H), 3.79 (dd, 
J = 10.2 Hz, J = 18.3 Hz, 1H), 5.47 (t, J = 7.8 
Hz, 1H), 7.35–7.78 (m, 7H), 8.88 (d, J = 2.1 Hz, 
1H), 8.99–9.06 (m, 2H), 9.88 (d, J = 2.1 Hz, 
1H). HRMS: calculated for C23H16N3O6 
430.1033; found 430.1036. 
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